<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl3" position="float">
 <label>Table 3</label>
 <caption>
  <title>
   <italic>In Vitro</italic> and 
   <italic>in Vivo</italic> Antiviral Activity of Some Potential Compounds against CoVs, Including SARS-CoV-2
  </title>
 </caption>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">no.</th>
    <th style="border:none;" align="center">compd</th>
    <th style="border:none;" align="center">reported mechanism of action</th>
    <th style="border:none;" align="center">
     <italic>in vitro</italic>/
     <italic>in vivo</italic>
    </th>
    <th style="border:none;" align="center">effect</th>
    <th style="border:none;" align="center">CoV type</th>
    <th style="border:none;" align="center">ref</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="9" style="border:none;" align="left">
     <bold>1</bold>
    </td>
    <td rowspan="9" style="border:none;" align="left">Chloroquine (CQ)</td>
    <td rowspan="9" style="border:none;" align="left">Increases endosomal pH; disrupts intracellular trafficking and viral fusion events; and interferes with glycosylation of cellular receptors of CoV.</td>
    <td rowspan="6" style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 1.13 μM; CC
     <sub>50</sub>: &gt;100 μM; SI: &gt;88
    </td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Wang et al.
     <sup>
      <xref ref-type="bibr" rid="ref16">16</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.33 μM; CC
     <sub>50</sub>: &gt;20 μM; SI: &gt;60
    </td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td style="border:none;" align="left">Shen et al.
     <sup>
      <xref ref-type="bibr" rid="ref1">1</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 4.1 μM; CC
     <sub>50</sub>: &gt;128 μM; SI: &gt;31
    </td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td rowspan="2" style="border:none;" align="left">de Wilde et al.
     <sup>
      <xref ref-type="bibr" rid="ref36">36</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 3.3 μM; CC
     <sub>50</sub>: &gt;50 μM; SI: &gt;15
    </td>
    <td style="border:none;" align="left">HCoV-229E</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.30 μM; CC
     <sub>50</sub>: 419 μM; SI: 1369
    </td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td style="border:none;" align="left">Keyaerts et al.
     <sup>
      <xref ref-type="bibr" rid="ref38">38</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 8.8 μM; CC
     <sub>50</sub>: 261 μM; SI: 30
    </td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Keyaerts et al.
     <sup>
      <xref ref-type="bibr" rid="ref37">37</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2" style="border:none;" align="left">Mouse model</td>
    <td style="border:none;" align="left">Intranasal administration of CQ (50 mg/kg BW) resulted in a minor reduction in viral titers in the lung.</td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Barnard et al.
     <sup>
      <xref ref-type="bibr" rid="ref79">79</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">A 98.6% survival of newborn C57BL/6 mice infected with HCoV-OC43 when mother mice were treated daily with CQ at a dose of 15 mg/kg BW.</td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td style="border:none;" align="left">Keyaerts et al.
     <sup>
      <xref ref-type="bibr" rid="ref38">38</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Open-label clinical trial</td>
    <td style="border:none;" align="left">Shorter median time to negative conversion and the duration of fever.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Huang et al.
     <sup>
      <xref ref-type="bibr" rid="ref39">39</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="5" style="border:none;" align="left">
     <bold>2</bold>
    </td>
    <td rowspan="5" style="border:none;" align="left">Hydroxychloroquine (HCQ)</td>
    <td rowspan="5" style="border:none;" align="left">The same as CQ.</td>
    <td style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.72 μM
    </td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Yao et al.
     <sup>
      <xref ref-type="bibr" rid="ref80">80</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Open-label, controlled clinical trial</td>
    <td style="border:none;" align="left">Significantly associated with viral load reduction/disappearance in COVID-19 patients. Synergetic effects when used in combination with azithromycin.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Gautret et al.
     <sup>
      <xref ref-type="bibr" rid="ref41">41</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Randomized controlled clinical trial</td>
    <td style="border:none;" align="left">Shorter time to clinical recovery and promoted the absorption of pneumonia.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Chen et al.
     <sup>
      <xref ref-type="bibr" rid="ref42">42</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Open-label, randomized controlled clinical trial</td>
    <td style="border:none;" align="left">No difference in negative conversion with standard of care alone in mild and moderate patients; higher adverse events such as diarrhea.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Tang et al.
     <sup>
      <xref ref-type="bibr" rid="ref44">44</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Open-label, controlled clinical trial</td>
    <td style="border:none;" align="left">No improvement in survival for COVID-19 patients who required oxygen.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Mahévas et al.
     <sup>
      <xref ref-type="bibr" rid="ref45">45</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="8" style="border:none;" align="left">
     <bold>3</bold>
    </td>
    <td rowspan="8" style="border:none;" align="left">Remdesivir (RDV)</td>
    <td rowspan="8" style="border:none;" align="left">Inhibits RdRp and blocks viral RNA synthesis; terminates the nonobligate chain.</td>
    <td rowspan="4" style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.77 μM; CC
     <sub>50</sub>: 100 μM; SI: &gt;129
    </td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Wang et al.
     <sup>
      <xref ref-type="bibr" rid="ref16">16</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.15 μM; CC
     <sub>50</sub>: &gt;10 μM; SI: &gt;66
    </td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td rowspan="2" style="border:none;" align="left">Brown et al.
     <sup>
      <xref ref-type="bibr" rid="ref51">51</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.024 μM; CC
     <sub>50</sub>: &gt;10 μM; SI: &gt;400
    </td>
    <td style="border:none;" align="left">HCoV-229E</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.06 μM; CC
     <sub>50</sub>: &gt;10 μM; SI: &gt;167
    </td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Agostini et al.
     <sup>
      <xref ref-type="bibr" rid="ref52">52</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Mouse model</td>
    <td style="border:none;" align="left">Ameliorated SARS-CoV-induced weight loss; reduced SARS-CoV-induced lung pathology and viral load in the lungs; and improved clinical signs of disease as well as respiratory function.</td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Sheahan et al.
     <sup>
      <xref ref-type="bibr" rid="ref53">53</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Observational, retrospective study</td>
    <td style="border:none;" align="left">Clinical improvement was observed in 36 of 53 patients (68%) in patients receiving oxygen support.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Grein et al.
     <sup>
      <xref ref-type="bibr" rid="ref55">55</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Double-blind, randomized, controlled clinical trial</td>
    <td style="border:none;" align="left">RDV was superior to placebo in shortening the time to recovery in patients with lower respiratory tract infection.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Beigel et al.
     <sup>
      <xref ref-type="bibr" rid="ref56">56</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Double-blind, randomized, controlled clinical trial</td>
    <td style="border:none;" align="left">No significant improvements in clinical or antiviral effects in severe patients.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Wang et al.
     <sup>
      <xref ref-type="bibr" rid="ref57">57</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2" style="border:none;" align="left">
     <bold>4</bold>
    </td>
    <td rowspan="2" style="border:none;" align="left">Favipiravir (FPV)</td>
    <td rowspan="2" style="border:none;" align="left">Inhibits RdRp and blocks viral RNA synthesis.</td>
    <td style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 61.8 μM; CC
     <sub>50</sub>: &gt;400 μM; SI: &gt;6.46
    </td>
    <td rowspan="2" style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Wang et al.
     <sup>
      <xref ref-type="bibr" rid="ref16">16</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Open-label, controlled clinical trial</td>
    <td style="border:none;" align="left">Significant shorter time to viral clearance and improvement in chest imaging compared with lopinavir/ritonavir, another antiviral drug.</td>
    <td style="border:none;" align="left">Cai et al.
     <sup>
      <xref ref-type="bibr" rid="ref62">62</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">Open-label, randomized, controlled clinical trial</td>
    <td style="border:none;" align="left">Did not significantly improve the clinical recovery rate on day 7 and did not shorten the latency to relief for pyrexia and cough.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Chen et al.
     <sup>
      <xref ref-type="bibr" rid="ref64">64</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="2" style="border:none;" align="left">
     <bold>5</bold>
    </td>
    <td rowspan="2" style="border:none;" align="left">Ribavirin</td>
    <td rowspan="2" style="border:none;" align="left">Inhibits viral RNA synthesis and mRNA capping.</td>
    <td rowspan="2" style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">The cytopathic effect of SARS-CoV was inhibited by ribavirin at 50 μg/mL</td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Chu et al.
     <sup>
      <xref ref-type="bibr" rid="ref66">66</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 109.5 μM; CC
     <sub>50</sub> &gt;400 μM; SI &gt;3.65
    </td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Wang et al.
     <sup>
      <xref ref-type="bibr" rid="ref16">16</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="4" style="border:none;" align="left">
     <bold>6</bold>
    </td>
    <td rowspan="3" style="border:none;" align="left">Lopinavir</td>
    <td rowspan="3" style="border:none;" align="left">Inhibits 3CL
     <sup>pro</sup> and blocks the cleavage of viral peptides into functional units.
    </td>
    <td rowspan="3" style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">The cytopathic effect of the SARS-CoV was inhibited by lopinavir at 4 μg/mL.</td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Chu et al.
     <sup>
      <xref ref-type="bibr" rid="ref66">66</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 17.1 μM; CC
     <sub>50</sub> &gt;32 μM; SI: &gt;2.0
    </td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td rowspan="2" style="border:none;" align="left">de Wilde et al.
     <sup>
      <xref ref-type="bibr" rid="ref36">36</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 6.6 μM; CC
     <sub>50</sub> &gt;37.6 μM; SI: 5.7
    </td>
    <td style="border:none;" align="left">HCoV-229E</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Lopinavir/ritonavir</td>
    <td style="border:none;" align="left">A fixed dose of ritonavir was used to increase lopinavir half-life through the inhibition of cytochrome P450.</td>
    <td style="border:none;" align="left">Randomized, controlled, open-label clinical trial</td>
    <td style="border:none;" align="left">No benefits in the time to clinical improvement and/or mortality rate at day 28 for severe COVID-19 patients, compared with standard care group.</td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Cao et al.
     <sup>
      <xref ref-type="bibr" rid="ref69">69</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">
     <bold>7</bold>
    </td>
    <td style="border:none;" align="left">Matrine sodium chloride</td>
    <td style="border:none;" align="left">Regulates immunity function and inhibits the release of inflammatory factors.</td>
    <td style="border:none;" align="left">Mouse model</td>
    <td style="border:none;" align="left">Intraperitoneal injection of matrine sodium chloride significantly improved the pathological damage of lung tissue and reduced lung index.</td>
    <td style="border:none;" align="left">HCoV-229E</td>
    <td style="border:none;" align="left">Jing et al.
     <sup>
      <xref ref-type="bibr" rid="ref73">73</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td rowspan="4" style="border:none;" align="left">
     <bold>8</bold>
    </td>
    <td rowspan="4" style="border:none;" align="left">Lycorine</td>
    <td rowspan="4" style="border:none;" align="left">Inhibits replication with an undefined mechanism.</td>
    <td rowspan="3" style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.0157 μM; CC: 14.9 μM; SI: 954
    </td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td style="border:none;" align="left">Li et al.
     <sup>
      <xref ref-type="bibr" rid="ref76">76</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.15 μM; CC: 4.37 μM; SI: 29.1
    </td>
    <td style="border:none;" align="left">HCoV-OC43</td>
    <td rowspan="3" style="border:none;" align="left">Shen et al.
     <sup>
      <xref ref-type="bibr" rid="ref1">1</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">IC
     <sub>50</sub>: 0.47 μM; CC: 3.81 μM; SI: 8.11
    </td>
    <td style="border:none;" align="left">HCoV-NL63</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Mouse model</td>
    <td style="border:none;" align="left">Intraperitoneal injection at 15 mg/kg provided an 83.3% protection for infected mice.</td>
    <td style="border:none;" align="left">HCoV-OC43</td>
   </tr>
   <tr>
    <td rowspan="2" style="border:none;" align="left">
     <bold>9</bold>
    </td>
    <td rowspan="2" style="border:none;" align="left">Camostat</td>
    <td rowspan="2" style="border:none;" align="left">Inhibits transmembrane protease serine 2.</td>
    <td style="border:none;" align="left">
     <italic>In vitro</italic>
    </td>
    <td style="border:none;" align="left">Blocked cellular entry of the SARS-CoV-2 virus into Caco-2 cells with an EC
     <sub>50</sub> of 1 μM.
    </td>
    <td style="border:none;" align="left">SARS-CoV-2</td>
    <td style="border:none;" align="left">Hoffmann et al.
     <sup>
      <xref ref-type="bibr" rid="ref78">78</xref>
     </sup>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Mouse model</td>
    <td style="border:none;" align="left">Protected mice against SARS-CoV lethal infection with a survival rate of 60%.</td>
    <td style="border:none;" align="left">SARS-CoV</td>
    <td style="border:none;" align="left">Zhou et al.
     <sup>
      <xref ref-type="bibr" rid="ref77">77</xref>
     </sup>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
